Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;8(2):98-108.
doi: 10.1007/s11899-013-0155-4.

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

A K Fielding  1 , G A Zakout
Affiliations
Review

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

A K Fielding et al. Curr Hematol Malig Rep. 2013 Jun.

Abstract

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by expression of oncogenic fusion product BCR-ABL1, resulting from reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)]. Previously perceived to confer poor outcome with at least 10 % lower chance of remission than standard-risk ALL. With the advent of targeted BCR-ABL specific tyrosine-kinase inhibitors (TKIs), higher remission rates were achieved, thus allowing more patients to proceed with the definitive treatment modality--allogeneic hematopoietic stem cell transplantation (alloHSCT). Prime challenges to treatment of Ph+ ALL include appropriate integration of TKIs into remission induction chemotherapeutic regimes, appropriate understanding and implementation of BCR-ABL monitoring for guiding therapeutic intervention(s), and minimizing transplant-related toxicities.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Nature. 2008 May 1;453(7191):110-4 - PubMed
    1. Cancer. 2007 May 15;109(10):2068-76 - PubMed
    1. Haematologica. 2007 Mar;92(3):401-4 - PubMed
    1. Blood. 2005 Jul 15;106(2):458-63 - PubMed
    1. Leukemia. 2013 Jun;27(6):1411-3 - PubMed

MeSH terms

Substances

LinkOut - more resources